Emerging Nano-Based Drug Delivery Approach for Cancer Therapeutics

Introduction

As several researchers have identified that cancer is the leading cause of mortality worldwide and finding a cure remains the big task for many researchers (Akshatha Prasanna et al 2018). Researchers identified that cancer is a major public health problem and becomes the second foremost cause of death worldwide (Kun Yu et al 2020). Recent views of the young and growing scientists are having the enough knowledge and moreover they are having the interest on Targeted cancer therapy. Because it can differentiate the small differences between normal and cancer cells. Targeted therapies are usually more effective than other predictable treatments and display lesser unwanted contrary effects. Since the non-specific and systemic drug delivery leads to rapid removal of drug, administration of the highest tolerable dose of the drug is needed which is not reasonable and usually exhibits high toxicity (Behdokht Bahrami et al 2017). Although different types of drug delivery methods are present the Doxorubicin (DOX) is also one of the most frequently used anticancer drugs in chemotherapy and drug delivery systems (Chang-Seuk Lee et al 2017). Advances in tumor biology can be successful once the drug delivery and therapy can be identified because as we know that cancer continues to be a prevalent and lethal disease (Dandan Wu et al 2017). One effective plan is engaged by nanoparticulate drug delivery systems to delivery therapeutic agents into cancer cells (Kai Dong et al 2018). The important mode of the carcinogenesis arises is due to the critical roles played by the chromosomal rearrangements and gene mutations (Mokwena Mpho Gift et al 2018).